A Phase II Study to Assess the Safety, Tolerability and Efficacy of Xanamem™ in Subjects With Mild Dementia Due to AD (XanADu)

Completed · Phase 2 · Has a placebo group

Conditions studied: Dementia, Alzheimer Type

In brief

This XanADu Phase II study in mild Alzheimer's Disease (AD) is to assess the safety, tolerability and efficacy of Xanamem in subjects with mild dementia due to Alzheimer's Disease. Subjects will be randomized to receive either 10mg once daily Xanamem or Placebo at a 1:1 ratio in a double-blinded fashion.

Key facts

Study ID

NCT02727699

Run by

Actinogen Medical

People needed

185

Starts

2017-03-23

Expected to finish

2019-03-15

Last updated by the study team

2025-02-03

Who can join

Age: 50 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Males and females aged 50 years or older at the time of informed consent.
• Female Subjects:
• Post menopausal women, defined as no menses for 12 months without an alternative medical cause. If there is any concern about the menopausal status of a prospective female subject, a follicle stimulating hormone test (FSH) should be requested to confirm post-menopausal status. Post menopausal women confirmed by FSH level > 40 mIU (milli-international units per milliliter) /mL, will be confirmed by central laboratory.
• Women of childbearing potential (WOCBP) must have a negative pregnancy test at Screening and Baseline, and be willing to use highly effective methods of contraception from the Screening visit until 3 months after last dose of study drug. If re-test is required, a local urine pregnancy test will be performed at Baseline to determine if the subject can continue to randomisation.
• Are permanently sterile or have had a hysterectomy, bilateral salpingectomy or bilateral oophorectomy.
• Women must not be breastfeeding.
• Male Subjects:
• Who are sexually active, fertile men must use highly effective methods of contraception from Day 1 until 3 months after last dose of study drug if their partners are WOCBP.
• Who are permanently sterile or have had bilateral orchiectomy.
• Diagnosis of mild dementia due to Alzheimer's disease (AD) with increased level of certainty (provided by evidence of clinical deterioration within the 6 months preceding Screening, as assessed by the investigator) as determined by the National Institute of Ageing (NIA) and the Alzheimer's Association (AA) workgroup.
• Mild dementia due to probable AD with Mini-Mental Status Examination (MMSE) 20 to 26 (inclusive).
• Clinical Dementia Rating Scale (CDR) Global Score of 0.5 to 1.0.
• A brain magnetic resonance imaging (MRI) or computed tomography (CT) scan in the 12 months preceding Screening that in the investigator's opinion is consistent with AD as the principle aetiology of the dementia with no other clinically significant abnormality, e.g. another principle underlying aetiology of the subject's dementia, or a lesion which could affect cognition e.g. a brain tumour or large stroke.
• On stable dose of acetylcholinesterase (AChEI) and/or memantine (at least 3 months prior to Screening) OR treatment-naïve. Initiating AChEIs or memantine during the study will not be permitted.
• Apart from a clinical diagnosis of mild dementia due to AD, the subject must be in good health as determined by the investigator, based on medical history and screening assessments.
• Has a consenting study partner who, in the investigator's judgement, has frequent and sufficient contact with the subject to be able to provide accurate information as to the subject's cognitive and functional abilities. The study partner must be available to provide information to the investigator and study site staff about the subject and agrees to attend all study site visits in person for scale completion. A study partner should be available for the duration of the study. The measure of adequate availability will be at the investigator's discretion.
• Must be willing and able to comply with the requirements of the protocol and must be available to complete the study.
• Must satisfy a medical examiner about their fitness to participate in the study.
• Must provide written informed consent to participate in the study.

You may not qualify if…

• Clinically significant abnormalities in vital signs (blood pressure, heart rate, respiration rate and oral temperature), as determined by the investigator.
• Clinically significant abnormal haematology, biochemistry and urine examination values, specifically abnormal liver and renal function and Vitamin B12 levels below lower threshold since these parameters may impact cognitive function, as determined by the investigator.
• Has had a significant systematic illness or infection within the past 4 weeks prior to randomisation, as determined by the investigator.
• Clinically significant neurological disease other than AD, such as (but not limited to) Parkinson's disease, multi-infarct dementia, Huntington's disease, normal pressure hydrocephalus, brain tumour, progressive supranuclear palsy, seizure disorder, subdural haematoma, multiple sclerosis or a history of significant head trauma followed by persistent neurologic defaults or known structural brain abnormalities.
• Subjects with clinical evidence of peripheral neuropathy or historical evidence of clinically significant nerve conduction abnormalities.
• Has had a stroke within the year prior to randomisation, as determined by the investigator.
• Has a lifetime diagnosis of a major psychiatric disorder (other than dementia), based on the Diagnostic and Statistical Manual of Mental Disorders, 4th Edition criteria. This includes but is not limited to schizophrenia, schizoaffective disorder, bipolar affective disorder, alcohol dependence syndrome or major depressive disorder.
• Has a history of disease directly related to the hypothalamus, the pituitary and/or the adrenal glands which affect the hypothalamic-pituitary-adrenal axis function.
• Has uncontrolled clinical conditions relating to glucose and lipid metabolism.
• Clinically significant electrocardiogram (ECG) abnormalities, including Corrected QT interval (QTc) > 450 ms, following ECG tracings at Screening.
• Use of any prohibited medication as detailed in the study protocol.
• Participation in another clinical study of an investigational drug or device whereby the last investigational drug/device administration is within 60 days of Screening.
• Inability to communicate well with the investigator (i.e. language problem, non-fluent English [as scales will be provided in English only], poor mental development or impaired cerebral function).
• Subject will undergo the tests, Alzheimer's Disease Assessment Scales (ADAS)-Cog v14, CDR-Sum of Boxes (SOB), MMSE, Neuropsychological Test Battery (NTB; executive domain) and RAVLT at the indicated time-points to avoid uncontrolled learning effects. Subjects who need to perform these tests externally to and in parallel with this study will be excluded.
• Subject has ingested any food or drink containing grapefruit, Seville oranges, star fruit or derived products (e.g. fruit juice), for at least 3 days prior to the first administration of study drug.

Where it is running

• Tucson Neuroscience Research, LLC — Tucson, Arizona, United States
• National Research Institute — Los Angeles, California, United States
• PCND Neuroscience Research Institute — Poway, California, United States
• Pacific Research Network, Inc. — San Diego, California, United States
• Research Alliance Inc. — Clearwater, Florida, United States
• The Neurology Research Group, LLC — Miami, Florida, United States
• Compass Research LLC — Orlando, Florida, United States
• IMIC, Inc. — Palmetto Bay, Florida, United States
• Atlanta Center for Medical Research — Atlanta, Georgia, United States
• NeuroStudies.Net, LLC — Decatur, Georgia, United States
• The NeuroCognitive Institute — Mount Arlington, New Jersey, United States
• Richmond Behavioral Associates — Staten Island, New York, United States
• PMG Research of Rocky Mount, LLC — Rocky Mount, North Carolina, United States
• The Clinical Trial Center — Jenkintown, Pennsylvania, United States
• Central Coast Neurosciences Research — Central Coast, New South Wales, Australia
• St Vincent's Hospital Sydney — Darlinghurst, New South Wales, Australia
• KaRa Institute of Neurological Diseases — Macquarie Park, New South Wales, Australia
• Medical & Cognitive Research Unit, Heidelberg Repatriation Hospital - Austin Health — Heidelberg West, Victoria, Australia
• Australian Alzheimer's Research Foundation — Nedlands, Western Australia, Australia
• The Research Institute for the Care of Older People — Bath, Combe Park, United Kingdom
• Manchester Mental Health & Social Care Trust - Dementia Research Office - Park House North Manchester General Hospital — Manchester, Lancashire, United Kingdom
• West London Mental Health Trust — Isleworth, London, United Kingdom
• St Pancras Clinical Research — Kings Cross, London, United Kingdom
• Institute of Clinical Sciences, Queen's University Belfast — Belfast, Northern Ireland, United Kingdom
• Centre for Clinical Brain Sciences, Centre for Dementia Prevention, The University of Edinburgh — Edinburgh, United Kingdom

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.